Zhejiang Orient Gene Biotech Co., Ltd. Class A
SSSE:68829817.75
CNY
-0.32
(-1.77%)
ISIN
CNE100003RM8
Return %
Stock
S&P 500
1Y
-29.95
14.20
3Y
-51.63
81.12
5Y
-77.96
68.34
Capital Structure
CNY
•
in mil. unless spec.Working Capital
CNY
•
in mil. unless spec.Growth Rates
CNY
•
in mil. unless spec.Quarterly Revenue
CNY
•
in mil. unless spec.Quarterly Earnings Per Share
CNY
•
in mil. unless spec.Quarterly Dividends Per Share
CNY
•
in mil. unless spec.Company Description
- CEO
- Xiao Liang Fang
- Full Time Employees
- 2,283
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- No. 3787, East Yangguang Avenue Huzhou SH China 313300
- IPO Date
- Feb 5, 2020
- Website
- orientgene.com
- Similar Companies
- Business
- Zhejiang Orient Gene Biotech Co., Ltd Zhejiang Orient Gene Biotech Co., Ltd researches, develops, manufactures and sells in-vitro diagnostic products principally focused on point-of-care testing (POCT) rapid diagnostic reagents; its core offerings include infectious disease tests such as COVID-19 antigen, IgG/IgM antibody, influenza, RSV and adenovirus combo kits, drugs of abuse detection panels, pregnancy and fertility tests including HCG strips, cardiac markers like troponin and CK-MB, tumor markers such as PSA and CEA, autoimmunity assays, non-infectious disease diagnostics, food safety tests and animal health products; the company also provides immunological fluorescence analyzer (IFA) solutions, quantum-beads flowcytometry systems for HPV, tumor markers, cardiac markers, allergy, cytokines and infections, dry biochemical strips, molecular diagnostics, FISH probes, raw materials and supporting instruments including analyzers. Zhejiang Orient Gene Biotech Co., Ltd operates three core platforms encompassing POCT rapid diagnostics, molecular diagnostics and liquid biochips, with infectious disease and toxicology comprising its flagship series that account for the majority of sales; approximately 95% of products are exported to over 100 countries across North America, South America, Europe, Asia, Africa and Oceania, serving healthcare providers, laboratories, third-party testing services and end-users globally. Founded in December 2005 and headquartered in Anji, Zhejiang Province, China, the company listed on the Shanghai Stock Exchange STAR Market (ticker: 688298.SS) in February 2020 and maintains subsidiaries including Healgen Scientific LLC and Healstone Biotech Inc. in the US, Qingdao Handsen Biotechnology Co., Ltd. and others in China; it employs around 2,276 people and holds provincial high-tech enterprise status with a complete industry chain from raw materials to instruments. Recent developments include the May 2025 EU IVDR certification for its COVID-19/Flu A&B/RSV/Adeno antigen combo test kit, showcasing expansion in multi-pathogen respiratory diagnostics; in May 2025, the company highlighted global respiratory testing advancements at industry events, and in February 2025 participated in MEDLAB Dubai to promote innovative products; ongoing efforts focus on industrial upgrading toward third-party testing services, sustained R&D investment at around 3% of revenue and stable partnerships with gene sequencing firms and research institutions like Zhejiang University.